[Objective]To evaluate the early clinical effectiveness of tranexamic acid, iron sucrose and recombinant human erythropoietin in the early postoperative phase after primary total hip arthroplasty. [Methods]Retrospective analysis was performed on 192 patients who underwent primary unilateral cementless total hip arthroplasty (THA) in the Department of Orthopedics, Peking University Third Hospital from July 2019 to June 2020. All cases were divided into TXA group, TXA iron group and combined drug group according to the blood management strategy. The cumulative blood loss, allogeneic transfusion rate, hemoglobin, hematocrit, erythrocyte count and their decreased levels in the early postoperative period were compared among the three groups. [Result]There were no significant differences in perioperative accumulative blood loss, allogeneic transfusion rate, hemoglobin, hematocrit, erythrocyte count and their decreased levels within 4 days after total hip arthroplasty among three groups(P > 0.05).[Conclusion]Tranexamic acid combined with iron sucrose and recombinant human erythropoietin did not effectively reduce the blood loss and allogeneic blood transfusion rate in the early 4 days after primary unilateral cementless total hip arthroplasty, and did not significantly improve the early postoperative anemia.